A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis
Principal Investigator
Vincent C. HoOverview
Study Start/End
Jun 25, 2019 to Dec 31, 2022Locations
Vancouver General HospitalName/Title
Grace Mak, Study CoordinatorPhone
604-875-5296Email Address
grace.mak@ubc.caPurpose of Study
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe AD who are candidates for systemic therapy.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.